(Q48358493)

10 February 2018

title

Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker (English)

1 reference

10 February 2018

Corrigendum to “Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker” [European Journal of Heart Failure 9/4 (2007) 429-434]

main subject

heart failure

0 references

corrigendum / erratum

0 references

author

Giuseppe De Vito

3

1 reference

10 February 2018

Stuart Galloway

object named as

Stuart Galloway

4

0 references

John McMurray

object named as

John McMurray

10

0 references

Naveed Sattar

7

object named as

Naveed Sattar

1 reference

10 February 2018

Colin Berry

1

1 reference

10 February 2018

Niamh F Murphy

2

1 reference

10 February 2018

Alison Seed

5

1 reference

10 February 2018

Carol Fisher

6

1 reference

10 February 2018

Patrick Vallance

8

1 reference

10 February 2018

W Sewart Hillis

9

1 reference

10 February 2018

publication date

27 November 2006

1 reference

10 February 2018

European Journal of Heart Failure

published in

1 reference

10 February 2018

volume

9

1 reference

10 February 2018

issue

4

1 reference

10 February 2018

page(s)

429-434

1 reference

10 February 2018

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Activation of neurohumoral systems in postinfarction left ventricular dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarctio

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Spironolactone improves lung diffusion in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Serious adverse events experienced by patients with chronic heart failure taking spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.10.005

10.1016/J.EJHEART.2006.10.005

21 January 2018

Identifiers

DOI

1 reference

10 February 2018

1 reference

10 February 2018